Xenon Seven

Xenon Seven

Senior Director, US Patient Marketing

Boston · Director

Sponsorship not specifiedDetected 119 days ago
RESTBrand StrategyVendor ManagementClinical TrialsPatient CareLeadershipCommunicationCollaboration

About the role

  • This position reports to the Vice President, Marketing and will be based out of Boston, MA, USA in our Needham office.
  • We will consider remote locations for exceptional candidates.
  • The level of the position will be commensurate with the candidate's education and industry experience.

Responsibilities

  • Serve as the Patient Marketing lead for U.S. launch readiness, ensuring patient programs, materials, and services are launch‑ready
  • Partner with cross‑functional launch teams to integrate patient marketing into overall brand and launch strategy
  • Lead development of an integrated, compliant patient engagement ecosystem, including digital, non‑personal, and field‑enabled channels
  • Leverage data, analytics, and insights to optimize patient engagement and personalize experiences over time
  • Partner closely with Patient Advocacy to ensure patient voices and perspectives are embedded across strategy, content, and programs

Requirements

  • Proven experience leading patient marketing strategy
  • outstanding project and budget management skills and track record for managing multiple vendors,
  • Ability to travel up to ~25%
  • Minimum undergraduate degree, advanced degree preferred. 12+ years of relevant experience or combination of degrees and experience.
  • Demonstrated success building and leading high‑impact teams in a matrixed environment; and collaborating and influencing cross-functionally
  • Deep understanding of regulatory and compliance requirements related to patient marketing
  • Strong strategic thinking, communication, and executive presence; outstanding project and budget management skills and track record for managing multiple vendors,

Nice to have

  • Minimum undergraduate degree, advanced degree preferred.
  • 12+ years of relevant experience or combination of degrees and experience.
  • US large category launch and epilepsy/neurology experience highly preferred

Compensation

  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance progr

Benefits

  • Lead the development of a comprehensive U.S. patient and caregiver marketing strategy, including unbranded disease education and branded patient engagement initiatives
  • Develop phased launch plans that evolve from pre‑launch education through post‑launch activation and adherence support
  • Oversee creation of patient‑focused content, tools, and resources that support education, onboarding, activation, and persistence

Company info

  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • What We Do:
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
  • We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
  • Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
  • In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
  • Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
  • We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
  • In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
  • We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
  • Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
Apply directly at Xenon Seven →Create a free account for alerts like thisView Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.